Mikko Gynther

My research focuses on the intricate role of drug transporters in pharmacokinetics, drug delivery, and anticancer drug therapy. I aim to explore and overcome transporter-mediated drug resistance and increase drug therapy efficacy and safety through innovative drug delivery strategies.

My core research interests are investigating transporters involved in anticancer drug resistance and developing novel methodologies to address these challenges. We aim to elucidate, through pharmacoproteomics, disease-induced alterations in transporter and enzyme expression, analyzing their implications for pharmacokinetics and drug delivery. As we continue pushing the boundaries of drug delivery systems, we are developing advanced mass spectrometry techniques for quantifying proteins from various biological samples, including cancer cells and tumor biopsies. This information is employed for the development of tumor-targeted drug delivery systems. In addition, we investigate novel strategies for modifying transporter expression in cancer cells to accumulate anticancer drugs in target cells efficiently.

With a strong background in drug transporters and quantitative proteomics, our team employs cutting-edge techniques to study transporter protein expression, cellular localization, and function. Our multidisciplinary approach fosters collaborations with local and international cancer research and nanoparticle development experts, enhancing our findings’ depth and breadth.